---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-018835"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:14:15.933761+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NeuroBo Q3 2023 net loss $3.8M; cash $25.8M; DA-1241 Phase 2a first patient dosed

## Summary
- Net loss $3.8M in Q3 2023 (EPS -$0.09) compared to net loss $3.1M (EPS -$3.50) in Q3 2022.
- Cash and cash equivalents $25.8M as of Sep 30, 2023; expected to fund operations into Q4 2024.
- First patient dosed in Phase 2a trial of DA-1241 for NASH; interim data expected H1 2024, full data H2 2024.
- DA-1726 IND submission for obesity expected by year-end 2023; Phase 1a initiation targeted H1 2024.
- Appointed James P. Tursi, M.D. to Board of Directors in November 2023.

## SEC filing metadata
- accession: 0001558370-23-018835
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837023018835/0001558370-23-018835-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837023018835/nrbo-20231113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-018835
- JSON: https://secwatch.observer/filing/0001558370-23-018835.json
- Plain text: https://secwatch.observer/filing/0001558370-23-018835.txt

## Key facts
- Earnings Releases
  MetaVia Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, NeuroBo Pharmaceuticals, Inc. (the “Company” ) issued a press release announcing its financial results for the third quarter ended September 30, 2023 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638287/000155837023018835/0001558370-23-018835-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.